Last ¥2,388 JPY
Change Today -53.00 / -2.17%
Volume 114.4K
4559 On Other Exchanges
Symbol
Exchange
Tokyo
As of 2:00 AM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

zeria pharmaceutical co ltd (4559) Snapshot

Open
¥2,412
Previous Close
¥2,441
Day High
¥2,433
Day Low
¥2,378
52 Week High
01/21/14 - ¥3,170
52 Week Low
12/17/13 - ¥1,934
Market Cap
126.8B
Average Volume 10 Days
109.9K
EPS TTM
¥81.68
Shares Outstanding
53.1M
EX-Date
09/26/14
P/E TM
29.2x
Dividend
¥30.00
Dividend Yield
1.16%
Current Stock Chart for ZERIA PHARMACEUTICAL CO LTD (4559)

Related News

No related news articles were found.

zeria pharmaceutical co ltd (4559) Related Businessweek News

No Related Businessweek News Found

zeria pharmaceutical co ltd (4559) Details

Zeria Pharmaceutical Co., Ltd. manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents. The company also provides cosmetics, health foods, alcoholic beverages, carbonated beverages, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, measuring equipment, and analytical equipment. Its ethical pharmaceutical products include functional dyspepsia treatment products, histamine h2 receptor antagonists, zinc containing anti-ulcerants, oral bowel cleansing products, laxative products, ulcerative colitis remedies, and proton pump inhibitors in the gastrointestinal field. The company’s products also include hypophosphatemia treatment products, long-acting calcium channel blockers, absorbable topical hemostats, sclerotherapy products for leg varicose veins, enzymatic hemostatics, anti-platelet oral jellies, oral non-steroidal anti-inflammatory products, anti-leukopenia after radiotherapy products, topical non-steroidal anti-inflammatory products, anti-inflammatory topical blood circulation enhancers, and non-steroidal anti-inflammatory ophthalmic solutions. In addition, Zeria Pharmaceutical Co., Ltd. offers OTC drugs and products, such as self-prevention products, remedies for gastrointestinal diseases, dermal remedies/cosmeceuticals, ophthalmic solutions, cold remedies, nutrient tonics, and topical anti-inflammatory analgesics. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Tokyo, Japan.

1,322 Employees
Last Reported Date: 06/27/14
Founded in 1955

zeria pharmaceutical co ltd (4559) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

zeria pharmaceutical co ltd (4559) Key Developments

Eisai Co., Ltd. and Zeria Pharmaceutical Co., Ltd. Conclude License Agreement Concerning a New Proton Pump Inhibitor in Japan

Eisai Co., Ltd. and Zeria Pharmaceutical Co., Ltd. announced that they have concluded a license agreement concerning E3710, a novel proton pump inhibitor (PPI) discovered and developed in-house by Eisai. Based on this agreement, Eisai will grant Zeria the exclusive rights to develop and co-promote, and the non-exclusive right to manufacture, E3710 in Japan. In addition, Eisai will receive down payment and additional royalties from Zeria, and after marketing authorization has been successfully obtained, Eisai will pay Zeria a certain consideration. While Zeria will develop E3710 and work to obtain marketing authorization, the two companies will collaborate on marketing E3710 after launch. E3710 is a novel PPI discovered by Eisai as a successor to Pariet, and compared to existing PPIs, potentially provides a stronger and a longer-lasting inhibitory effect on gastric acid secretion. E3710 shows promise as a best-in-class treatment which could shorten the treatment period and meet the needs of patients for whom existing PPIs are inadequate. This license agreement will enhance the product pipeline of Zeria, who focuses on gastrointestinal diseases as a key franchise area, and maximize the value of Eisai's compound. Both Eisai and Zeria have a strong track record in the field of gastrointernal diseases (Eisai with the PPI Pariet and the gastritis /gastric ulcer treatment Selbex, Zeria with the ulcerative colitis treatment Asacol and the world's first functional dyspepsia treatment Acofide) and will conduct co-promotional activities with the aim of bringing a product to the market for acid related diseases as soon as possible. Through this collaboration on E3710, Eisai and Zeria aim to satisfy the medical needs of acid related diseases and further contribute to the treatment of patients.

Zeria Pharmaceutical Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2014; Provides Consolidated Earnings Guidance for the First Six Months and Full Year of Fiscal 2015; Provides Second Quarter and Yearend Dividend Guidance for Fiscal 2015

Zeria Pharmaceutical Co., Ltd. announced consolidated earnings results for the first quarter ended June 30, 2014. For the quarter, the company reported net sales of ¥14,715 million, operating income was ¥858 million, ordinary income of ¥943 million and net income was ¥1,048 million or ¥19.74 per share compared to net sales of ¥15,340 million, operating income was ¥2,853 million, ordinary income of ¥3,082 million and net income was ¥2,435 million or ¥53.56 per share for the same period a year ago. Net assets per share as of June 30, 2014 was ¥1,113.30 compared to ¥1,105.78 as of March 31, 2014. The company provided consolidated earnings guidance for the first six months and full year of fiscal 2015 ending March 31, 2015. For the first six months, the company expected net sales of ¥32,000 million, operating income was ¥3,500 million, ordinary income of ¥3,500 million and net income was ¥2,900 million or ¥54.60 per share. For the full year, the company expected net sales of ¥69,000 million, operating income was ¥7,400 million, ordinary income of ¥7,400 million and net income was ¥5.800 million or ¥109.19 per share. The company also provided second quarter and yearend dividend guidance for fiscal 2015. The company expected to pay second quarter dividend of ¥15.00 per share for fiscal 2015 compared to ¥14.00 per share paid for the same period a year ago. The company expected to pay yearend dividend of ¥15.00 per share for fiscal 2015 compared to ¥15.00 per share paid for the same period a year ago.

Zeria Pharmaceutical Co., Ltd. to Report Q1, 2015 Results on Aug 05, 2014

Zeria Pharmaceutical Co., Ltd. announced that they will report Q1, 2015 results on Aug 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4559:JP ¥2,388.00 JPY -53.00

4559 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4559.
View Industry Companies
 

Industry Analysis

4559

Industry Average

Valuation 4559 Industry Range
Price/Earnings 27.3x
Price/Sales 1.9x
Price/Book 2.0x
Price/Cash Flow 30.3x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZERIA PHARMACEUTICAL CO LTD, please visit www.zeria.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.